Physician profile
James A Coder, III
NPI 1811923949
$580.02
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.50 · 2020: $42.69 · 2021: $256 · 2022: $185.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $101.45 | 2020-2022 | |
| Abbvie INC. | $91.49 | 2021-2022 | |
| Novo Nordisk INC | $91.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $62.56 | 2021-2022 | |
| Sanofi Pasteur INC. | $42.79 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $35.72 | 2022 | |
| Lilly USA, LLC | $34.52 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $29.81 | 2021 | |
| Biofire Diagnostics, LLC | $17.04 | 2019 | |
| Althera Pharmaceuticals LLC | $16.37 | 2021 | |
| Seqirus USA INC | $15.51 | 2022 | |
| Allergan, INC. | $15.23 | 2019 | |
| Currax Pharmaceuticals LLC | $13.66 | 2021 | |
| Alk-Abello, INC | $12.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Coder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.